Archive · 8 Jan 2026
Healthcare Investments Surge in 2025
In 2025, healthcare investments reached new highs.
Globally, private equity deals hit a record $191 billion, with a lot of big deals and more buyouts.
The money made from selling these investments also went up a lot.
In India, there were more healthcare companies going public, but the average amount they raised was less, and their stock prices didn't go up as much on the first day.
Experts think this is because the market is being more careful.
The biopharma and healthcare provider sectors were the most active.
Places like Japan, India, and Australia saw a lot of growth.
Some people are excited about the future of healthcare investments, while others are more cautious because of market volatility.
Global healthcare private equity deal value hit a record $191 billion in 2025, with 445 buyouts announced.
Exit value rebounded to $156 billion, up from $54 billion in 2024, driven by large deals and sponsor-to-sponsor transactions.
Biopharma and provider segments led the market, with biopharma deals reaching $80 billion and over 130 deals.
Asia-Pacific saw record deal value, with notable growth in Japan, India, and Australia.
In India, healthcare IPOs surged with 11 companies raising ₹12,317 crore, but average issue sizes and listing-day returns declined.
- Who
- Global and Indian healthcare investors, including private equity firms and IPO issuers
- What
- Record healthcare private equity deal value and a surge in healthcare IPOs in India
- When
- 2025
- Where
- Global, with notable activity in Asia-Pacific and India
- Why
- Increase in large deals, rebound in exit activity, and structural maturation of the healthcare sector
Optimistic View
Cautious View
Market Performance
Optimistic View
Investors are optimistic about the healthcare sector due to its stable growth potential and defensive nature, especially in regions like Asia-Pacific.
Cautious View
Market volatility and cautious secondary market conditions have led to a decline in average issue sizes and listing-day returns, indicating investor risk aversion.
IPO Trends
Optimistic View
The surge in healthcare IPOs signals structural maturation and provides exit routes for early investors, driven by strong domestic liquidity.
Cautious View
The increase in IPO volumes is largely due to smaller, less established companies entering the market, which has diluted average deal sizes and post-IPO performance.
- Global PE Deal Value
- $191 billion
- Global PE Deal Volume
- 445 buyouts
- Global Exit Value
- $156 billion
- Biopharma Deal Value
- $80 billion
- Biopharma Deal Volume
- 130+ deals
- India IPO Volume
- 11 healthcare companies
- India IPO Fundraising
- ₹12,317 crore
- Average Issue Size in India
- ₹1,120 crore
- Average Listing Gain in India
- 14.07%
